Evista was originally proposed as a drug for osteoporosis and now FDA has approved it for use for patients with breast cancer. It is a drug made by Eli Lilly originally meant to treat osteoporosis patients. It is highly recommended for women in the postmenopausal stage with osteoporosis with high risk for breast cancer or already having cancer. It is already approved for osteoporosis in women past their menopause.
The drug however comes with a warning. It has side effects, which could be fatal. It has been noticed that those on Evista are not prone to strokes but in case they have one they could prove very dangerous. There seemed to be a higher death rate in those who were on Evista.
Lilly has decided to carry a warning to patients in the form of a “black box ‘ which tells them certain basic facts. This is one of the strictest warning an American drug can carry. The drug is allowed to stay in the market if it carries the dreaded black box warning. Now it is up to the patient and the doctors to decide whether the advantages outweigh the disadvantages or not. Despite these warnings and studies Evista had the sale of $278 million in the second quarter